Media Articles Related to Ganirelix
Infertility treatment 'does not affect offspring's early development'
Source: Fertility News From Medical News Today [2016.01.05]
In a new study, researchers found no difference in the risk of early developmental disabilities between children conceived through infertility treatment and those who were not.
Active, Passive Smoking Tied to Infertility, Early Menopause: Study
Source: MedicineNet Birth Defects Specialty [2015.12.16]
Title: Active, Passive Smoking Tied to Infertility, Early Menopause: Study
Category: Health News
Created: 12/15/2015 12:00:00 AM
Last Editorial Review: 12/16/2015 12:00:00 AM
Male Infertility Might Signal Higher Odds of Testicular Cancer
Source: MedicineNet Testicular Cancer Specialty [2015.11.16]
Title: Male Infertility Might Signal Higher Odds of Testicular Cancer
Category: Health News
Created: 11/16/2015 12:00:00 AM
Last Editorial Review: 11/16/2015 12:00:00 AM
For Unexplained Infertility, Breast Cancer Drug No Better Than Standard Treatment
Source: MedicineNet letrozole Specialty [2015.09.24]
Title: For Unexplained Infertility, Breast Cancer Drug No Better Than Standard Treatment
Category: Health News
Created: 9/23/2015 12:00:00 AM
Last Editorial Review: 9/24/2015 12:00:00 AM
Infertility Pictures Slideshow: Which Treatment Is Right for You?
Source: MedicineNet Endometrial Biopsy Specialty [2014.05.01]
Title: Infertility Pictures Slideshow: Which Treatment Is Right for You?
Created: 12/10/2010 5:53:00 PM
Last Editorial Review: 5/1/2014 12:00:00 AM
Published Studies Related to Ganirelix
A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. [2011.06.30]
We performed a randomized trial to compare IVF outcomes in 54 poor responder patients undergoing a microdose leuprolide acetate (LA) protocol or a GnRH antagonist protocol incorporating a luteal phase E(2) patch and GnRH antagonist in the preceding menstrual cycle.
The effect of cetrorelix vs. ganirelix on pregnancy outcome using minimal gonadotropin stimulation in women with elevated day 3 serum follicle stimulating hormone levels. 
CONCLUSIONS: The trend for lower pregnancy rates with ganirelix vs. cetrorelix seen in women with diminished egg reserve is consistent with the findings of a study performed in women with normal egg reserve using a normal gonadotropin stimulation regimen. It is not clear if the adverse effect is on the endometrium or the embryo.
Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. [2006.03]
BACKGROUND: This study was designed to assess whether the use of ganirelix in women undergoing stimulated IUI could prevent the occurrence of premature LH rises and luteinization (LH+progesterone rises)... CONCLUSIONS: Treatment with ganirelix effectively prevents premature LH rises, luteinization in subjects undergoing stimulated IUI. Low-dose rFSH regimen combined with a GnRH antagonist may be an alternative treatment option for subjects with previous proven luteinization or in subjects who would otherwise require insemination when staff are not working.
LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome. [2005.12]
Elevated LH concentration is a common feature in polycystic ovary syndrome (PCOS). This study was designed to establish whether elevated LH levels in PCOS might be suppressed to normal range values by the administration of different low doses of GnRH antagonist, which subsequently might reverse the anovulatory status of these patients...
Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. [2005.07]
OBJECTIVE: To compare the safety and efficacy of single-dose cetrorelix acetate (3 mg) and daily ganirelix acetate (0.25 mg) in the inhibition of premature LH surge in women undergoing cycle-programmed ovarian stimulation before Assisted Reproductive Technology (ART).CONCLUSION(S): Cetrorelix and ganirelix effectively prevented LH surges in oral contraceptive (OC) pill-programmed, flexible protocols, with similar safety profiles and PRs; however, cetrorelix required significantly fewer injections, increasing patient convenience.